{
    "2021-12-02": [
        [
            {
                "time": "",
                "original_text": "“植发第一股”雍禾医疗港股IPO认购 年末港股打新掀高潮",
                "features": {
                    "keywords": [
                        "雍禾医疗",
                        "港股IPO",
                        "年末",
                        "打新",
                        "高潮"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "前后脚披露罕见大单，博腾、凯莱英接到70亿合同，疑似为新冠口服药",
                "features": {
                    "keywords": [
                        "博腾",
                        "凯莱英",
                        "大单",
                        "新冠口服药",
                        "合同"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "跨年行情如何布局？机构普遍看好这三大赛道",
                "features": {
                    "keywords": [
                        "跨年行情",
                        "布局",
                        "机构",
                        "赛道"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "【国金医药】凯莱英点评：港股发行区间公布，未来增长再提速",
                "features": {
                    "keywords": [
                        "国金医药",
                        "凯莱英",
                        "港股发行",
                        "增长提速"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国金证券维持凯莱英买入评级：港股发行区间公布，建议重点关注",
                "features": {
                    "keywords": [
                        "国金证券",
                        "凯莱英",
                        "买入评级",
                        "港股发行",
                        "重点"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "全球小分子CDMO领跑者，凯莱英(6821.HK/002821.SZ)赴港上市",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "CDMO",
                        "赴港上市",
                        "全球领跑者"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "东吴证券月度策略及金股组合——从震荡走向春季躁动",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "月度策略",
                        "金股组合",
                        "春季躁动",
                        "震荡"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "九洲药业逾2亿元收购亏损药厂 转型CDMO需跟踪产能空间 亏损",
                "features": {
                    "keywords": [
                        "九洲药业",
                        "收购",
                        "亏损药厂",
                        "转型CDMO",
                        "产能空间"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}